A multiplex quantitative proteomics strategy for protein biomarker studies in urinary exosomes  by Raj, Delfin A.A. et al.
A multiplex quantitative proteomics strategy for
protein biomarker studies in urinary exosomes
Delfin A.A. Raj1,2, Immacolata Fiume1, Giovambattista Capasso2 and Gabriella Pocsfalvi1
1Laboratory of Mass Spectrometry and Proteomics, Institute of Protein Biochemistry – CNR, Naples, Italy and 2Division of Nephrology,
Faculty of Medicine, Department of Internal Medicine, Second University of Naples, Naples, Italy
Urinary exosomes have received considerable attention as
a potential biomarker source for the diagnosis of renal
diseases. Notwithstanding, their use in protein biomarker
research is hampered by the lack of efficient methods for
vesicle isolation, lysis, and protein quantification. Here we
report an improved ultracentrifugation-based method that
facilitates the solubilization and removal of major impurities
associated with urinary exosomes. A double-cushion sucrose/
D2O centrifugation step was used after a two-step differential
centrifugation to separate exosomes from the heavier
vesicles. After the removal of uromodulin, 378 and 79 unique
proteins were identified, respectively, in low- and high-
density fractions. Comparison of our data with two previously
published data sets helped to define proteins commonly
found in urinary exosomes. Lysis, protein extraction, and
in-solution digestion of exosomes were then optimized for
MudPIT application. More than a hundred exosomal proteins
were quantified by four-plex iTRAQ analysis of single and
pooled samples from two different age groups. For healthy
men, six proteins (TSN1, PODXL, IDHC, PPAP, ACBP, and
ANXA5) showed significant expression differences between
exosome pools of those aged 25–50 and 50–70 years old.
Thus, exosomes isolated by our method provide the basis for
the development of robust quantitative methods for protein
biomarker research.
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Single-protein biomarkers support the molecular diagnosis
and medical management of various disorders in clinical
practice today. Urine is one of the most attractive biomarker
sources for large-scale noninvasive clinical screening pro-
grams. Sample variability, complexity, and the wide dynamic
concentration range of urinary proteins, however, present a
significant analytical challenge for biomarker discovery.1
Therefore, the number of high-throughput high-confidence
urinary protein biomarkers identified by proteomic ap-
proaches currently is still somewhat limited.
Exosomes are extracellular membrane-bound nanovesicles
originating from the intraluminal vesicles of multivesicular
bodies secreted by diverse cell types under both normal and
pathological conditions.2 Despite their role in immune system
modulation,3 the biological role of exosomes remained elusive
until Lo¨tvall’s group demonstrated that exosomes can transfer
genetic information from one cell to another.4 Exosomes were
shown to transport proteins, mRNAs, and microRNAs and to
modulate immune reaction, angiogenesis, cell proliferation,
and tumor cell invasion. Consequently, their use in biomarker
research as a source of disease-relevant cargo proteins shows
great promise. Exosomes have been isolated from various
biofluids including urine.5 Application of proteomics to
urinary exosomes secreted by the urinary tract epithelial cells
has recently been reviewed.6,7 The limited progress of urinary
exosomes in biomarker discovery can be explained by the high
and variable concentration of uromodulin, also referred to as
Tamm–Horsfall glycoprotein, and the lack of protocols
enabling urinary exosomal proteins for quantitative proteo-
mics. Uromodulin assembles into intracellular filaments
forming three-dimensional matrix. This filament network
traps exosomes and prevents their efficient isolation and
purification by the traditional methods.8,9 To overcome this
problem, recently, dithiothreitol was used to reduce the
intermolecular disulfide bonds of uromodulin.8,10 Treatment
with dithiothreitol results in a somewhat higher yield of
urinary exosomes; however, it does not seem to work in all
cases. This prompted us to revise and improve the current
isolation method. We have set up new protocols for the
isolation/purification and also for the lysis and subsequent
solubilization of membrane proteins to meet the need of
protein biomarker discovery platform. Quantitative proteo-
mics based on iTRAQ labeling and MudPIT was applied to
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demonstrate the feasibility of multiplex quantitative approach.
For the iTRAQ experiment, four samples were prepared
(Table 1) with the aim of detecting differences in the pro-
teomes of urinary exosomes of (i) an individual and their
age-matched pooled control, (ii) individuals of two different
age groups, and (iii) two different exosome preparations
(conventional single-cushion and new double-cushion) in a
single multiplex analysis.
RESULTS
Isolation and purification of urinary exosomes by impurity
solubilization and double-cushion ultracentrifugation
Current urinary exosome isolation and purification methods are
based on ultracentrifugation or filtration. In the two-step
differential centrifugation protocol,10 first a low-velocity sequen-
tial centrifugation is performed to remove cells and cellular
debris. The second step is ultracentrifugation of the supernatant
at 100,000–200,000g velocity to sediment urinary vesicles.
Vesicles isolated by differential centrifugation are contaminated
by abundant urinary proteins (uromodulin, albumin, etc.) and
are heterogeneous in size. To isolate more homogeneous vesicle
population at a higher purity grade, the crude preparation is
further processed by sucrose gradient or sucrose cushion
centrifugation. The latter uses a small density cushion typically
composed of 1mol/l sucrose in deuterium oxide (D2O) for the
separation of exosomes by the formation of a micro-gradient.2
Although sucrose gradient and cushion centrifugations allow a
better separation of vesicles of different sizes, it does not solve
the problem of the co-purifying uromodulin.11
We aimed to find suitable conditions for the solubilization
of uromodulin aggregates in order to shift uromodulin from
the vesicle-containing layer into the soluble protein fraction
during the cushion centrifugation. We have found that
20mmol/l Tris, pH 8.6, buffer facilitates the solubilization
of filaments and keeps uromodulin in solution. To improve
the separation of exosomes from the heavier vesicles and/or
membrane fragments, the single cushion was replaced by a
double cushion. In this step, the crude exosome pellet
solubilized in the Tris buffer is centrifuged on a double layer
composed of 1 and 2mol/l sucrose in D2O. Qualitative
transmission electron microscopy image of the 1-mol/l
fraction shows small (30–50 nm in diameter) intact membrane
vesicles with the typical morphology of exosomes (Figure 1b).
Fewer filaments and more homogeneous vesicle distributions
can be observed in this preparation than in vesicles obtained
by the conventional single-cushion method (Figure 1a). In the
2-mol/l fraction, larger urinary vesicles and aggregates were
detected (Figure 1c). Starting with 1000ml urine, the process
yields vesicles containing 100mg of proteins in the 1-mol/l
fraction and 10mg in the 2-mol/l fraction. SDS-polyacryl-
amide gel electrophoresis (PAGE) and western blot analyses
performed at different steps of the process show how the
amount of co-purifying uromodulin is reducing at each step
(Figure 2a, lanes 3–6). By comparing the SDS-PAGE and
western blot images of the 1-mol/l fraction (Figure 2, lane 6)
with the urinary vesicles prepared by the conventional
differential centrifugation (Figure 2, lane 3) and single-
cushion (Figure 2, lane 8) methods, clear improvements in
protein pattern (Figure 2a) and quantity of exosome markers
(Figure 2b) were seen. Vesicles were purified five times from
the same biological sample (pooled samples of 10 healthy
male donors) with good reproducibility (Figure 3). Different
Table 1 | The four urinary exosome samples analyzed using iTRAQ labeling and MudPIT quantitative proteomics
Sample
number
Exosome preparation
method Age (years)
Number of
individuals
Sample volume per
individual (ml)
Sampling
method Label
1a Double cushion 25–45 20 50 Pooled iTRAQ-114
2 Double cushion 50–70 20 50 Pooled iTRAQ-115
3 Double cushion 43 1 1000 Single iTRAQ-116
4a Single cushionb 25–45 20 50 Pooled iTRAQ-117
aSamples 1 and 4 were prepared from the same pool of individual urine samples.
bUrinary vesicles prepared by the single-cushion method using phosphate-buffered saline buffer.
100 nm 100 nm 100 nm
Figure 1 |Qualitative transmission electron microscopy analysis of urinary vesicles purified by the single-cushion method using
phosphate-buffered saline buffer and the double-cushion method using 20mmol/l Tris, pH 8.6. (b) The typical size distribution and
shape of exosome-type urinary vesicles in the 1-mol/l sucrose/D2O fraction after density centrifugation. (c) The presence of larger vesicles
and aggregates in the 2-mol/l sucrose/D2O fraction. Size distribution of exosomes purified by the double-cushion method (b) is more
homogeneous and contains fewer filaments than vesicles purified by the traditional single-cushion method (a).
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biological replicates resulted in similar pattern too (Figure 3).
We also purified urinary vesicles from patients having micro-
and macro-proteinuria and found very similar SDS-PAGE
pattern to that of healthy people (data not shown).
Interestingly, the two vesicle fractions (1 and 2mol/l) show
a very different SDS-PAGE pattern (Figure 2), which was
further investigated in a proteomic study.
In-gel digestion and MudPIT-based proteomics of urinary
vesicles isolated by double-cushion centrifugation
The 1- and 2-mol/l fractions obtained by double-cushion
centrifugation were subjected to in-gel and in-solution
digestion–based proteomic analyses. Proteins identified by at
least two unique peptides and Po0.05 significance are
reported in Supplementary Tables online. In all, 378 and 79
unique proteins were identified in the 1- and 2-mol/l fractions,
respectively. Proteins in the main SDS-PAGE bands of the
2-mol/l fraction (semenogelin 1, semenogelin 2, olfactomedin,
PSCA, and PPAP) previously have been identified in seminal
prostasomes.12 It was therefore reasonable to deduce that the
2-mol/l fraction contains vesicles heavier than exosomes, such
as urinary-secreted prostasomes. Of 79 proteins, 15 proteins,
including MASP2 and MUC6 prostasomal proteins, are
present only in the 2-mol/l fraction, whereas the remaining
(64 proteins) were found to be common in the two sets. The
identified proteins were functionally annotated using the open-
source protein annotation tool, STRAP.13 The systems biology
modeling, which included gene ontology and canonical genetic
pathway analysis, shows that urinary exosomes are particularly
enriched in proteins involved in biological regulation
and binding (Figure 4). Indeed, 33 different Ras-related
Rab proteins, known regulators of different steps of
membrane traffic, including vesicle formation and movement,
were identified. Different components of endosomal sorting
complexes required for transport (ESCRT), such as ESCRT-I
(VPS28, VPS37B, and VPS37D), ESCRT-II (VPS25), ESCRT-
III (CHMP1B, CHMP2A, CHMP2B, CHMP4B, and CHMP5),
and VPS4 (VPS4A, VPS4B, and VTA1), with a known role in
exosome biogenesis were also identified. Ten and four proteins
from the protein families of Annexins and Copines, respec-
tively, with known calcium-dependent phospholipid-binding
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Figure 2 | SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot (WB) analyses showing the different stages of
urinary exosome isolation/purification process. (a) SDS-PAGE and (b) WB images. L1, total urine; L2, exosome-depleted urine; L3, crude
exosome after differential centrifugation; L4, 15,000g pellet; L5, 15,000g supernatant; L6, exosomes purified in the 1-mol/l sucrose fraction
by double-cushion method using 20mmol/l Tris, pH 8.6; L7, urinary vesicles purified in the 2-mol/l sucrose fraction by the double-cushion
method; L8, exosomes purified by the single-cushion method using phosphate-buffered saline buffer; M, protein molecular mass market.
Western blots were probed with antibodies against the following market proteins: Na-K-Cl cotransporter isoform 2 (NKCC2), apoptosis-
linked gene-2-interacting protein X (ALIX), Nap/Hp exchanger 3 (NHE3), tumor susceptibility gene 101 (TSG101), b-ACTIN, aquaporin 2
(AQP2), and CD9.
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Figure 3 | SDS-polyacrylamide gel electrophoresis (PAGE)
image shows a good analytical reproducibility of the double-
cushion sample preparation method of urinary exosomes
using a pooled sample of healthy volunteers in five
consecutive experiments (left, lanes A1–A5). Exosomes
isolated/purified from two different pooled samples of healthy
volunteers show (right, lanes B1 and B2) very similar SDS-PAGE
patterns too. Lane M: protein molecular mass marker.
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properties were identified too. Another binding protein family
highly represented in our data set (by 13 proteins identified) is
the guanine nucleotide–binding proteins (G-proteins) involved
as modulators and transducers in various transmembrane
signaling systems. In addition, CD9, CD38, CD55, CD59, and
CD63 antigens present on the surface of exosomes and known
to participate in immune regulation were identified. These
findings are in line with the key biological functions of
exosomes discovered recently in cell–cell communication and
in the modulation of different cellular mechanisms including
the immune system. Therefore, the proteomes of urinary
vesicles obtained by this improved isolation and purification
process (Supplementary Tables online) may provide a promis-
ing source for robust and reproducible biomarker discovery
studies.
Cross-comparison with published data sets
A detailed comparison was performed between the proteins
identified in the 1-mol/l fraction of the double-cushion
ultracentrifugation and two previously published data
sets using differential centrifugation10,14 and microfiltration15
in combination with mass spectrometry (MS)-based protein
identification (Supplementary Table S1B online). For this
comparison, only proteins identified with at least two unique
peptides were considered. So far, the largest data set comes
from the work of Knepper’s group,10,14 publicly available in
the Urinary Exosome Database (http://dir.nhlbi.nih.gov/
papers/lkem/exosome/). The data set is built on two gel-
based, large-scale proteomic studies using two different types
of ion-trap instruments for peptide analysis. The data set
includes proteins identified in pooled samples of healthy
volunteers (male and female) of different age. It reports 531
proteins that have been identified with at least two unique
peptides. Merchant et al.,15 on the other hand, identified 94
proteins by isolating exosomes using microfiltration and in-
solution digestion–based shotgun method from a pooled
urine sample. Figure 5 shows the Venn diagram of the
comparison (Supplementary Table S1B online). Out of the
378 proteins identified in our work (Supplementary Table
S1A online), 216 and 48 proteins were found to overlap with
Gonzales14 and Merchant15 data sets, respectively. It should
be noted that, in spite of the variability of the biological
sample and difference in methodologies, the overlap with
Gonzales’s data set is relatively high (46%). In total, there are
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Figure 4 | STRAP bar charts showing the biological process gene ontology (GO) term annotation distributions (upper) and
molecular function GO term annotation distributions (lower) of the identified exosomal proteins (1mol/l fraction, Supplementary
Table S1A online) and proteins identified in the higher-density urinary vesicles (2mol/l fraction, Supplementary Table S2 online).
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247 proteins that have been identified by at least two of the
three methods. These we considered as the common and
most readily identifiable proteins of urinary exosomes, and
we called them as the ‘the core urinary exosome proteome’.
The core protein set was cross-checked against a data set
containing 1416 entries from exosome studies conducted on
human cell lines and biological fluids (except urine) extracted
from the ExoCarta database16 (Supplementary Table S1C
online). Out of the 247 core proteins, 171 proteins (69%)
were found to be identified in biological sources other than
urine, whereas 76 proteins (31%) were specific of urine.
Some of these can be contaminants (such as uromodulin),
whereas others (such as membranes of solute carrier family
12) could be true exosomal proteins specific to the epidermal
cells lining the urinary tract. In a similar way, we compared
those proteins that have been identified by only one of the
three methods. Proteins identified only by this work overlap
with a higher percentage (50%, 78 out of 156) with the
human exosomal proteins listed in ExoCarta (Supplementary
Table S1C online) compared with the data sets of Gonzales
(41%) and Merchant (38%). This is in accordance with the
transmission electron microscopy (Figure 1), SDS-PAGE
(Figure 2a), western blot (Figure 2b), and STRAP (Figure 4)
analysis, and indicates a higher content of true exosomal
proteins and lower contamination in sample prepared by the
double-cushion method.
Multiplex quantitative proteomics strategy for the relative
quantification of urinary exosomal proteins
In-solution digestion–based quantitative strategy is being
increasingly applied to the discovery phase of protein
biomarker research in clinical proteomics over the tedious
gel-based analysis. In urinary exosome research, however, it is
hampered by inefficient lysis and solubilization of highly
resistant lipid vesicles, resulting in low protein yield and
altered protein composition. Here we show that using an acid-
cleavable detergent (RapiGest) can greatly facilitate vesicle
lysis, protein solubilization, and proteolysis enhancement for
downstream liquid chromatography–mass spectrometry (LC-
MS/MS) analysis of the proteins of urinary vesicles. The
detergent is cleaved and easily removed after digestion by
solid-phase extraction. Figure 6 shows the experimental setup
used in this work. The iTRAQ labeling method was used to
measure protein relative abundances. Table 1 displays the
samples for iTRAQ run, and Figure 7 shows the SDS-PAGE
images of the samples before the labeling reaction. Samples
were prepared in parallel according to the single- and double-
cushion protocols from a pooled urine sample of 20 healthy
male donors in the age group of 25–45 years. Effects of age and
sample pooling on the relative protein quantities were
monitored in the same experiment. A total of 114 proteins
were quantified, and the measured weighted median protein
ratios are reported in Table 2. A twofold change was
considered to be biologically significant in this analysis. The
results confirm that the isolation/purification method does
highly influence the protein abundances (Table 2, ratio 117/
114). A total of 37 exosomal proteins show a significantly
decreased level in the sample prepared by the single-cushion
method. In addition, a 20-fold increase in uromodulin was
detected. On comparing the two different age groups (Table 2,
ratio 115/114), significant differences were found in six
proteins. Interestingly, altered expressions of five out of these
six proteins (TSN1, PODXL, IDHC, PPAP, and ANXA5) have
been implicated in cancer and cancer prognosis. In all, 12
downregulated and 9 upregulated proteins were found to be
differently expressed when a pooled sample of 20 individuals
was compared with that of a single person. Most prominently,
higher levels of Annexin-1 (5.3-fold), PSCA (4.8-fold), and
Aquaporin-2 (2.9-fold), and lower level of PDXL (7.8-fold),
were measured in the single sample. These observations
indicate that while pooling individual samples certainly
reduces biological variation but can potentially hide biological
significance.
DISCUSSION
The objective of this study was to solve the problem of co-
purifying urinary proteins in the preparation of urinary
exosomes and to set up protocols that allow the MudPIT-
based strategy for the quantification of exosomal proteins. The
major barrier for protein biomarker studies through urinary
exosomes is the presence of highly abundant urinary proteins
forming polymeric networks and entrapping the vesicles. As a
first step, we developed a method for the efficient isolation
and purification of urinary exosomes based on impurity
solubilization and sucrose double-cushion centrifugation. We
show that uromodulin and other cytoplasmic filament contamina-
tions can be efficiently removed by the method (Figures 1 and
2), whereas the vesicles remain intact (Figure 1). The method
enables the separation of exosomes from larger vesicles, such
as prostasomes (Figure 1). Next, we set up a new protocol for
the lysis of exosomes and subsequent solubilization of mem-
brane proteins by using a commercial acid-cleavable detergent.
This step was found to be fundamental to successfully
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Figure 5 |Comparison of proteins identified in urinary
exosomes isolated/purified in the 1-mol/l sucrose/D2O
fraction in this work with previously published data sets
corresponding to the microfiltration15 and differential
centrifugation10,14 (Supplementary Table S1B online).
Dark gray indicates a set of common proteins identified by at
least two of the methods. Light gray shows proteins identified
by only one of the methods.
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interface urinary exosome preparation method with current
in-solution digestion-based quantitative proteomics. Urinary
vesicles recovered from the two cushions were analyzed by
gel-based and, for the first time by, in-solution digestion–-
based proteomics. Proteomic analyses identify fewer proteins
in the new preparations than previous analysis in earlier
Urine
Double-cushion centrifugation Single-cushion centrifugation
Sample preparation
Vesicles
Peptides
Vesicle lysis, protein
solubilization, reduction,
alkylation, tryptic digestion
Labeled
peptides
iTRAQ labelingiTRAQ 114 iTRAQ 115 iTRAQ 116 iTRAQ 117
Combining of labeled peptides
Cation exchange chromatographySCX column 
Reversed-phase chromatographyMonolithic column
Nano-ESI-MS/MS
MS/MS
fragmentation
iTRAQ
reporter ions
Data normalization and statistical
analysis
Figure 6 | Flowchart showing the four-plex iTRAQ labeling and the MudPIT quantitative proteomics approach applied for urinary
exosomes in this work. ESI-MS/MS, electrospray ionization tandem mass spectrometry.
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Figure 7 |Comparison of the four urinary exosome samples (Table 1) prepared for the multiplex quantitative proteomic workflow
(Figure 6). SDS-polyacrylamide gel electrophoresis (a) and western blot (b) analyses of the four exosome samples (Table 1) prepared for the
quantitative iTRAQ analysis. Samples 1–3 were prepared by the double-cushion method using 20mmol/l Tris, pH 8.6, and sample 4 was
prepared by the single-cushion method using phosphate-buffered saline buffer (conventional preparation). L1, exosomes isolated from a
pooled sample of 20 healthy male volunteers in the age group of 25–50 years; L2, exosomes isolated from a pooled sample of 10 healthy
male volunteers in the age group of 50–70 years; L3, exosomes isolated from a pooled sample of a male individual aged 43 years; L4,
exosomes isolated by the single-cushion method from a pooled sample of 20 healthy male volunteers in the age group of 25–50 years; Lane
M, protein molecular mass marker. Western blots (b) were probed with antibodies against the following marker proteins: Na–K–Cl
cotransporter isoform 2 (NKCC2), apoptosis-linked gene-2-interacting protein X (ALIX), Naþ /Hþ exchanger 3 (NHE3), tumor susceptibility
gene 101 (TSG101), b-ACTIN, aquaporin 2 (AQP2), and CD9.
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Table 2 |Weighted median ratios of urinary exosomal proteins quantified in the 4-plex iTRAQ experiment using MudPIT
quantitative proteomics
UniProt ID Protein name
Mascot
score No. pep.a
No. pep.
used for
quant.b Cov. %c
115/
114d
116/
114d
117/
114d
AMPN_HUMAN Aminopeptidase N 2125 426 384 43 0.8 1.4 0.3
IST1_HUMAN IST1 homolog 1050 178 138 37 1.0 0.6 0.4
DPEP1_HUMAN Dipeptidase 1 600 111 89 54 0.8 0.7 0.4
ACTB_HUMAN Actin, cytoplasmic 1 513 130 114 46 1.4 1.5 0.7
VPS4A_HUMAN Vacuolar protein sorting-associated protein 4A 503 142 88 36 1.1 0.7 0.5
NEP_HUMAN Neprilysin 493 171 124 44 0.9 1.0 0.4
PDC6I_HUMAN Programmed cell death 6-interacting protein 411 121 79 39 1.1 0.7 0.4
UROM_HUMAN Uromodulin 372 100 74 19 1.0 0.4 19.4
EZRI_HUMAN Ezrin 361 188 148 47 1.2 1.1 0.7
CHM2A_HUMAN Charged multivesicular body protein 2a 350 58 31 29 1.2 1.5 0.6
PSCA_HUMAN Prostate stem cell antigen 346 24 24 21 1.3 5.4 0.3
GGT1_HUMAN Gamma-glutamyltranspeptidase 1 342 86 65 20 0.8 1.0 0.4
AQP1_HUMAN Aquaporin-1 327 33 26 23 0.9 0.7 0.6
ANX11_HUMAN Annexin A11 326 128 117 35 1.4 0.5 0.6
RS27A_HUMAN Ubiquitin-40S ribosomal protein S27a 324 120 108 46 1.0 0.7 0.5
CHMP5_HUMAN Charged multivesicular body protein 5 315 51 42 46 1.0 0.6 0.2
HSP7C_HUMAN Heat shock cognate 71 kDa protein 304 49 36 32 1.2 1.0 0.4
VPS4B_HUMAN Vacuolar protein sorting-associated protein 4B 280 114 71 45 1.1 0.6 0.5
CDC42_HUMAN Cell division control protein 42 homolog 264 31 27 18 1.0 1.7 0.2
XPP2_HUMAN Xaa-Pro aminopeptidase 2 252 48 37 22 1.0 1.5 0.5
SDCB1_HUMAN Syntenin-1 243 49 37 28 0.8 0.5 0.5
PROM1_HUMAN Prominin-1 239 47 34 26 0.9 0.5 0.4
POTEE_HUMAN POTE ankyrin domain family member E 235 67 46 14 1.3 1.3 0.6
DPP4_HUMAN Dipeptidyl peptidase 4 220 126 66 37 1.0 0.8 0.4
MOES_HUMAN Moesin 215 109 78 35 1.2 1.1 0.8
CHM4B_HUMAN Charged multivesicular body protein 4b 213 44 28 31 1.3 0.9 0.6
THY1_HUMAN Thy-1 membrane glycoprotein 189 38 35 24 1.3 2.2 0.4
S12A1_HUMAN Solute carrier family 12 member 1 178 77 59 18 1.3 0.8 0.7
MGA_HUMAN Maltase-glucoamylase, intestinal 172 51 35 12 1.2 2.9 0.4
RADI_HUMAN Radixin 165 122 96 24 1.2 1.1 0.8
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B 156 34 25 25 1.3 0.9 0.5
MUC1_HUMAN Mucin-1 153 68 59 5 1.0 0.5 0.8
ACTC_HUMAN Actin, alpha cardiac muscle 1 145 60 51 30 1.4 1.6 0.7
1433E_HUMAN 14-3-3 Protein epsilon 138 24 21 25 1.7 1.6 0.6
MDR1_HUMAN Multidrug resistance protein 1 134 22 7 14 1.4 1.5 0.5
ANXA5_HUMAN Annexin A5 133 32 12 50 3.1 2.0 1.2
PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 127 21 19 34 1.4 1.6 0.8
ACE_HUMAN Angiotensin-converting enzyme 116 21 9 14 0.9 1.2 0.5
CAN7_HUMAN Calpain-7 111 50 18 21 1.0 0.6 0.5
CD9_HUMAN CD9 antigen 111 22 20 7 1.0 0.4 0.4
LDHB_HUMAN L-Lactate dehydrogenase B chain 104 26 18 30 1.5 2.1 0.8
PGK1_HUMAN Phosphoglycerate kinase 1 102 27 21 30 1.4 1.4 0.8
BROX_HUMAN BRO1 domain-containing protein BROX 100 60 30 56 1.1 0.6 0.4
1433Z_HUMAN 14-3-3 Protein zeta/delta 99 23 18 26 1.7 1.7 0.6
LAMP2_HUMAN Lysosome-associated membrane glycoprotein 2 98 19 13 12 1.2 0.4 0.3
GTR5_HUMAN Solute carrier family 2, facilitated glucose transporter
member 5
94 30 17 13 0.7 0.3 0.2
BASP1_HUMAN Brain acid soluble protein 1 89 9 7 38 1.9 1.0 0.8
AQP2_HUMAN Aquaporin-2 84 17 11 14 1.5 2.9 0.7
1433B_HUMAN 14-3-3 Protein beta/alpha 80 26 18 33 1.7 1.6 0.6
GBG12_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(O)
subunit gamma-12
75 11 11 41 1.0 1.3 0.7
S12A3_HUMAN Solute carrier family 12 member 3 73 36 19 10 1.3 1.6 0.7
PC5C_HUMAN G-protein coupled receptor family C group 5 member C 72 20 15 16 0.7 0.3 0.9
ALDOB_HUMAN Fructose-bisphosphate aldolase B 72 16 11 15 1.1 2.8 0.6
TSN1_HUMAN Tetraspanin-1 71 7 7 5 0.4 0.6 0.1
VTA1_HUMAN Vacuolar protein sorting-associated protein VTA1
homolog
70 32 21 27 1.0 0.7 0.3
PDCD6_HUMAN Programmed cell death protein 6 69 37 25 25 1.1 0.6 0.5
1433T_HUMAN 14-3-3 Protein theta 67 20 15 23 1.7 1.6 0.6
ANXA7_HUMAN Annexin A7 65 21 8 10 1.7 0.9 0.5
ANXA4_HUMAN Annexin A4 64 23 16 32 1.6 2.0 0.5
MYO1C_HUMAN Myosin-Ic 63 13 5 12 1.3 1.4 0.5
Table 2 Continued on the following page
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Table 2 | Continued
UniProt ID Protein name
Mascot
score No. pep.a
No. pep.
used for
quant.b Cov. %c
115/
114d
116/
114d
117/
114d
GPC5B_HUMAN G-protein coupled receptor family C group 5 member B 63 16 6 9 0.7 0.2 1.0
ACBP_HUMAN Acyl-CoA–binding protein 63 19 12 50 2.6 1.4 0.8
ANXA6_HUMAN Annexin A6 60 34 14 26 1.5 1.6 0.8
UPK1A_HUMAN Uroplakin-1a 60 18 11 19 1.1 1.6 0.3
GNAS2_HUMAN Guanine nucleotide–binding protein G(s) subunit alpha
isoforms short
60 21 10 29 1.5 1.1 0.8
BHMT1_HUMAN Betaine–homocysteine S-methyltransferase 1 59 12 9 13 1.3 4.8 0.5
ARF1_HUMAN ADP-ribosylation factor 1 59 9 4 40 1.3 1.3 0.7
1433F_HUMAN 14-3-3 Protein eta 58 18 14 12 1.7 1.6 0.6
PPIA_HUMAN Peptidyl-prolyl cis–trans isomerase A 57 30 13 43 1.3 1.1 0.5
KIF12_HUMAN Kinesin-like protein KIF12 55 19 2 22 1.0 1.7 0.9
TS101_HUMAN Tumor susceptibility gene 101 protein 55 16 8 29 1.1 0.6 0.5
CAH2_HUMAN Carbonic anhydrase 2 54 23 11 39 1.7 2.0 1.2
MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate 53 4 3 20 1.4 1.8 1.1
GNA13_HUMAN Guanine nucleotide-binding protein subunit alpha-13 50 11 7 19 1.5 1.1 0.7
GNAL_HUMAN Guanine nucleotide-binding protein G(olf) subunit alpha 50 13 9 13 1.5 1.1 0.8
CTL4_HUMAN Choline transporter-like protein 4 49 14 10 6 1.1 0.7 0.5
GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit alpha-2 49 13 6 18 1.5 1.1 0.8
GNAI3_HUMAN Guanine nucleotide-binding protein G(k) subunit alpha 49 12 6 15 1.5 1.1 0.8
GNAT1_HUMAN Guanine nucleotide-binding protein G(t) subunit alpha-1 49 10 6 16 1.5 1.1 0.8
PPAP_HUMAN Prostatic acid phosphatase 48 10 6 17 2.1 0.7 0.6
UPK2_HUMAN Uroplakin-2 48 16 7 29 1.1 1.2 0.4
IDHC_HUMAN Isocitrate dehydrogenase [NADP] cytoplasmic 47 6 3 15 2.1 1.7 0.6
CD59_HUMAN CD59 glycoprotein 47 7 6 17 1.0 0.8 0.3
ES8L2_HUMAN Epidermal growth factor receptor kinase substrate 8-like
protein 2
45 11 5 13 1.3 1.0 0.6
AMPE_HUMAN Glutamyl aminopeptidase 45 28 8 15 0.8 0.5 0.5
CE032_HUMAN UPF0467 protein C5orf32 45 5 4 10 1.1 0.7 0.5
NHRF1_HUMAN Na(+)/H(+) exchange regulatory cofactor NHE-RF1 44 10 6 24 1.1 1.3 0.6
PRDX6_HUMAN Peroxiredoxin-6 44 22 11 43 2.4 1.9 0.8
HSP76_HUMAN Heat shock 70 kDa protein 6 44 11 4 12 1.3 0.8 0.5
GBB2_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T)
subunit beta-2
42 22 15 16 1.2 1.1 0.6
EHD1_HUMAN EH domain-containing protein 1 41 40 30 17 1.2 1.2 0.6
CTL2_HUMAN Choline transporter-like protein 2 41 23 10 10 1.2 0.7 0.6
ANXA1_HUMAN Annexin A1 40 9 3 25 — — 0.6
VASN_HUMAN Vasorin 40 12 3 11 0.7 1.3 0.9
RHOA_HUMAN Transforming protein RhoA 38 7 3 27 1.1 1.0 0.8
RHOC_HUMAN Rho-related GTP-binding protein RhoC 38 7 3 24 1.1 1.0 0.8
RHOB_HUMAN Rho-related GTP-binding protein RhoB 38 5 3 23 1.1 1.0 0.8
COF1_HUMAN Cofilin-1 38 6 2 29 1.5 1.4 0.8
ENOA_HUMAN Alpha-enolase 37 49 25 31 1.7 1.7 1.0
GSTM3_HUMAN Glutathione S-transferase Mu-3 37 7 6 20 1.7 2.3 0.8
TPIS_HUMAN Triosephosphate isomerase 37 9 3 33 1.5 1.6 1.2
SC5A2_HUMAN Sodium/glucose cotransporter 2 36 11 7 7 1.3 0.5 0.5
GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T)
subunit beta-1
36 23 12 16 1.3 1.1 0.7
PSDE_HUMAN 26S proteasome non-ATPase regulatory subunit 14 36 11 9 6 1.1 0.6 0.4
LCMT2_HUMAN Leucine carboxyl methyltransferase 2 35 8 6 6 0.6 1.0 0.4
CNDP2_HUMAN Cytosolic nonspecific dipeptidase 34 26 8 30 1.0 1.3 0.7
PODXL_HUMAN Podocalyxin 34 17 8 10 0.5 0.1 0.4
PROF1_HUMAN Profilin-1 33 4 2 27 1.2 0.9 0.8
NAPSA_HUMAN Napsin-A 33 5 3 7 1.0 2.0 0.7
RAP1B_HUMAN Ras-related protein Rap-1b 33 10 7 30 1.8 2.0 0.9
OLFM4_HUMAN Olfactomedin-4 31 7 4 9 0.7 0.4 0.4
S23A1_HUMAN Solute carrier family 23 member 1 28 6 3 4 1.2 1.4 0.6
ACY1_HUMAN Aminoacylase-1 28 11 3 13 1.4 2.4 0.5
F16P1_HUMAN Fructose-1,6-bisphosphatase 1 27 6 3 14 1.8 1.5 0.6
Proteins upregulated and downregulated at least by twofold are highlighted in dark gray and in light gray, respectively.
aNumber of peptides used for protein identification.
bNumber of peptides used for protein quantification.
cPercentage of sequence coverage relative to the identification.
dWeighted median ratios measured in the 4-plex iTRAQ experiment. Sample labeling is according to Table 1.
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preparations (Supplementary Tables online). This is partly
due to the removal of contaminating urinary proteins and
partly to the use of stringent criteria we applied for protein
identification. In fact, the majority of the proteins present in
the exosome database today have been identified based on a
single peptide and needs to be revised. It is demonstrated that
the methodological improvements in the preparation of urinary
exosomes facilitate in-solution digestion, iTRAQ labeling,
and MudPIT-based quantitative proteomics (Figure 6).
In a preliminary study, the effects of age and sample pooling
on protein expression have been studied (Figure 7). We
found significant difference in six exosomal protein expres-
sions when comparing two different age groups of healthy
individuals (Table 2). On the other hand, preliminary data
suggest that the sample pooling possibly compromises the
results of the analysis.
MATERIALS AND METHODS
Urine collection
Second morning urine samples (up to 200ml) were collected from
healthy male volunteers of two age groups: 25–50 and 50–70 years.
Protease inhibitors, sodium azide, phenylmethylsulfonyl fluoride, and
leupeptin (AppliChem, Darmstadt, Germany) were prepared and
added to the samples according to Pisitkun et al.10 and Zhou et al.17
Samples were stored at 80 1C until processed.
Isolation of urinary vesicles by differential centrifugation and
single-cushion centrifugation
Urine samples were thawed, extensively vortexed, and subjected to
iterative sequential centrifugations at 400, 800, and 15,000g velocity
for 20min at each step at 4 1C to remove whole cells, large membrane
fragments, and other debris. The supernatant was centrifuged at
200,000g for 1 h at 4 1C using a Beckman 70 Ti rotor (Beckman
Coulter, Fullerton, CA), and urinary vesicle containing pellet (crude
exosome) was recovered. Crude exosome pellet was resuspended in
28ml phosphate-buffered saline (PBS; 150mmol/l NaCl at pH 7.2),
under-layered by a single cushion composed of 1mol/l sucrose
prepared in PBS/D2O, and centrifuged at 110,000g for 3 h at 4 1C using
a Beckman SW 32 Ti rotor. The vesicles captured within the sucrose
layer were collected, washed twice in PBS buffer, and centrifuged at
110,000g for 90min at 4 1C using a SW 32 Ti rotor. The pellet was
resuspended in 100–150ml PBS buffer.
Exosome isolation and purification by the double-cushion
method
The crude exosome pellet was resuspended in 28ml of 20mmol/l
Tris, pH 8.6, solubilization buffer and centrifuged at 15,000g for
20min at 4 1C. The supernatant was subjected to cushion ultracen-
trifugation using a double layer. For this step, exosome sample was
under-layered without disturbing the interface in the ultracentrifuge
tube by 5.2ml 1mol/l sucrose and 3.5ml 2mol/l sucrose prepared in
20mmol/l Tris pH 8.6/D2O and centrifuged at 110,000g for 3 h at
4 1C using a SW 32 Ti rotor. The vesicles captured in the 1- and 2-
mol/l cushions were collected, washed twice in solubilization buffer,
and centrifuged at 110,000g for 90min, at 4 1C using a SW 32 Ti
rotor. Pellets were resuspended in 100–150 ml solubilization buffer.
Protein concentrations were determined by the micro-bicinchoninic
acid protein assay (Pierce/Thermo Scientific, Rockford, IL). Samples
were stored at 80 1C until use.
Transmission electron microscopy
Urinary vesicles (2–3 mg) were mixed at a ratio of 1:1 with 4%
paraformaldehyde and applied onto glow-discharged carbon-coated
200-mesh copper grids. The adsorbed exosomes were stained with
freshly prepared 2.0% aqueous uranyl acetate and embedded in a
mixture of uranyl acetate (0.4%) and methyl cellulose (0.13%). The
samples were examined using a JEM-1011 transmission electron
microscope (JEOL, Tokyo, Japan) at 100 kV.
SDS-PAGE analysis
Protein samples (20mg) were electrophoretically separated on a
precast Novex 4–12% Bis-Tris NuPAGE gel using MOPS running
buffer (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions and stained with colloidal Coomassie blue.
Western blotting
Immunoblot (western blot) analysis of proteins was performed on
proteins separated by SDS-PAGE. The stained gel was destained in
water, soaked in 1% SDS (pH 8.5) for 30min, and washed twice in
water and once using the NuPAGE Transfer Buffer (Invitrogen) for
10min. Proteins were transferred onto polyvinylidene difluoride
membranes (Invitrogen), blocked according to the manufacturer’s
instruction, and probed with mouse monoclonal antibodies: tumor
susceptibility gene 101 (TSG101), apoptosis-linked gene-2-interact-
ing protein X (ALIX), b-actin (b-ACTIN), Naþ /Hþ exchanger 3
(NHE3), CD9 (Santa Cruz Biotechnology, Santa Cruz, CA), and
rabbit polyclonal antibodies aquaporin 2 (AQP2) and Na–K–Cl
cotransporter isoform 2 (NKCC2; gift from G Capasso). The blots
were incubated with alkaline phosphatase–conjugated secondary
antibodies, and the immune complexes were detected using a
Western Light chemi-luminescent detection system (Applied Biosys-
tems, Bedford, MA) according to the manufacturer’s protocol.
Gel-based proteomic analysis
Entire gel lanes were cut into 1.5-mm bands, proteins were reduced,
alkylated, in-gel trypsin digested, and extracted as described
earlier.18 The peptides were analyzed by nanoflow reversed-phase
liquid chromatography electrospray ionization tandem mass spec-
trometry (LC-ESI-MS/MS) as described for the iTRAQ experiment,
except that the length of the gradient was 17min.
Lysis, iTRAQ labeling, and quantitative MudPIT analysis
Urinary exosome sample was solubilized in 0.8% RapiGest SF
(Waters, Milford, MA) and lysed by three freeze–thaw cycles in
liquid nitrogen under sonication. Proteins (100 mg) were reduced,
alkylated, digested with trypsin, and labeled with iTRAQ reagents
(Applied Biosystems, Foster City, CA) according to the manufac-
turer’s instruction with the following minor modifications. After the
labeling reaction, the four samples were pooled and 10 ml of 20% (v/
v) trifluoroacetic acid was added to cleave RapiGest. Samples were
vortexed, incubated at 37 1C for 1 h, and centrifuged. The super-
natant was vacuum-dried, resolubilized in 5% (v/v) methanol, and
peptides were purified by solid-phase extraction using Oasis column
(Waters) according to manufacturer’s instructions. iTRAQ-labeled
peptides were separated by two-dimensional liquid chromatography
using SCX chromatography in the first dimension and reversed-
phase chromatography in the second dimension. SCX was
performed using a Polysulfoethyl-Asp column, 1.0mm ID 15 cm
length (LCPackings, Sunnyvale, CA), with the following conditions:
95% solvent A (20% acetonitrile, 0.05% formic acid) and 5% solvent
B (20% acetonitrile, 0.05% formic acid, 500mmol/l KCl) for 3min,
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solvent B ramped up to 90% for 40min and maintained for 7min at
100%. Over a period of 55min with a flow rate of 40 ml/min, 47
fractions were collected, dried, and analyzed in the second
dimension using a nanoflow LC, Ultimate 3000 (Dionex, Sunnyvale,
CA). Samples of volume 20 ml were loaded, purified, and
concentrated on a reversed-phase monolithic pre-column, 200mm
ID 5mm length (LCPackings), at a flow rate of 25 ml/min. Peptides
were separated at a flow rate of 300 nl/min on a PepSwift Monolithic
column, 100mm ID 5 cm length (LCPackings), using the following
gradient: (solvent C: 2% acetonitrile, 0.1% formic acid; solvent D:
98% acetonitrile, 0.1% formic acid) 5–50% D for 90min, 50–98% D
in 6 s and 98% D for 10min. Eluted peptides were analyzed in
information-dependent acquisition mode using QSTAR Elite (Ap-
plied Biosystems) equipped with a nanoflow electrospray ion source.
Data analysis
The Analyst QS 2.0. software (Applied Biosystems, Foster City, CA)
was used with default parameters to generate and analyze peak lists
extracted from information-dependent acquisition mass spectra.
Mascot v.2.2 (Matrix Science, London, UK) was used to search data
against SwissProt 2010_09 database (519348 sequences) using
trypsin with one possible missed cleavage. Proteins identified by
in-gel digestion proteomics, carbamidomethylation of cysteine, and
oxidation of methionine were considered as fixed and variable
modifications, respectively. An analysis of the false-positive rate of
the protein identifications was performed by searching all tandem
mass spectra from the nano-HPLC-ESI-MS/MS analyses against an
in-house curated decoy SwissProt human protein database contain-
ing forward and reverse sequences. In addition, contaminants such
as human keratins, porcine trypsin and so on were included in this
database. The false-positive rate analysis resulted in the identifica-
tion of 4397 unique peptides from the target database as compared
with 71 peptides from the decoy database. On the basis of this
analysis, we estimate the percentage of false-positives to be 1.61%
for the present peptide data set. For quantitative analysis, iTRAQ
modification at lysine residue and at the N termini of the peptide
and carbamidomethylation of cysteines were set as fixed modifica-
tions. Oxidation of methionine and iTRAQ modification at tyrosine
residues were set as variable modifications. Mass tolerance was set to
50 p.p.m. for precursor and to 0.1Da for fragment ions. Mascot
iTRAQ four-plex quantification method was used for peptide and
protein quantification. The protein ratio was calculated as a
weighted median ratio. Criteria for protein identification and quan-
tification were as follows: a minimum of two unique peptides and
Po0.05 significance threshold using MudPIT scoring. Open-source
STRAP13 was used to obtain gene ontology (GO) terms associated
with the urinary exosomal protein identified by proteomics.
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